糖皮质激素应用于肝衰竭治疗机制及其临床时机的把握

doi:10.3969/j.issn.1672-5069.2020.01.004

Abstract

Fan Wenhan, Luo Yiping, Li Chengzhong. Application of steroids in treatment of patients with liver failure[J]. Journal of Practical Hepatology, 2020, 23(1): 7-9.

References 20

[1]	中华医学会感染病学分会肝衰竭与人工肝学组;中华医学会肝病学分会重型肝病与人工肝学组.肝衰竭诊治指南(2018年版).实用肝脏病杂志,2019,22(2):164-171.
[2]	Singal AK,Shan VH.Current trials and novel therapeutic targets for alcoholic hepatitis.J Hepatol,2019,70(2):305-313.
[3]	Triantafyllou E,Woollard KJ,Mcphail MJW,et al.The role of monocytes and macrophages in acute and acute-on chronic liver failure.Front Immunol,2018,9(12):2948.
[4]	Chung RT, Stravitz RT, Fontana RJ, et al. Pathogenesis of liver injury in acute liver failure. Gastroenterology, 2012,143: e1-e7.
[5]	Dong X, Gong Y, Zend H,et al. Imbalance between circulating CD4+ regulatory T and conventional T lymphocytes in patients with HBV-related acute-on-chronic liver failure. Liver Int, 2013, 33:1517-1526.
[6]	王晓晶, 张小平, 宁琴. 肝衰竭的免疫发病机制. 临床肝胆病杂志,2014, 30: 984-991.
[7]	Ma TL, Hu TH, Hung CH, et al. Incidence and predictors of retreatment in chronic hepatitis B patients after discontinuation of entecavir or tenofovir treatment. PLoS One, 2019,14(10):e0222221.
[8]	Puengel T, Tacke F. Repair macrophages in acute liver failure.Gut, 2018,67(2): 202-203.
[9]	Yan Z,Tan W,Zhao W,et al. Regulatory polymorphisms in the IL-10 gene promoter and HBV-related acute liver failure in the Chinese population.J Viral Hepat,2009,16(11):775-783.[10] Staud F, Ceckpva M, Micuda S, et al. Expression and function of p-glycoprotein in normal tissues: effect on pharmacokinetics.Methods Mol Biol,2010, 596:199-222.
[11]	Iqbal M, Gibb W, Matthews SG. Corticosteroid regulation of P-glycoprotein in the developing blood-brain barrier. Endocrinology, 2011, 152(3):1067-1079.
[12]	Foucaud-Vignault M, Soavfane Z, Menez C,et al.P-glycoprotein dysfunction contributes to hepatic steatosis and obesity in mice. PLoS One, 2011, 6(9):e23614.
[13]	Bernal W,Jalan Quaglia A.Acute-on-chronic liver failure.Lancet,2015,386(10003):1576-1587.
[14]	Hoofnagle JH.Reactivation of hepatitis B.Hepatology, 2009,49:S156-S165.
[15]	中华医学会感染病学分会肝衰竭与人工肝学组,中华医学会肝病学分会重型肝病与人工肝学组.肝衰竭诊治指南.中华临床感染杂志,2012,5:321-327.
[16]	Wong VW,Wong GL,Yiu KK,et al.Entecavir treatment in patient swith severe acute exacerbation of chronic hepatitis B. J Hepatotol,2011,54:236-242.
[17]	Fujiwara K,Yasui S,Okitsu K,et al.The requirement for a sufficient period of corticosteroid treatment in combination withnucleoside analogue for severe acute exacerbation of chronic hepatitis B.J Gastroenterol,2010,45:1255-1262.
[18]	Li J,Wu J,Liu HX,et al.Early bilirubin response in acute on chronic hepatitis B liver failure patients treated with corticosteroids predicates a lower 3-month mortality.Int J Clin exp Med,2016,9:10364-10373.
[19]	Zhang XQ,Liang L,You JP,et al.Efficacy of short term dexamethasone therapy in acute on chronic pre-liver failure.Hepatol Res,2011,41:46-53.
[20]	Fujiwara K, Nakano M, Yasui S, et al. Advanced histology and impaired liver regeneration are associated with disease severity in acute-onset autoimmune hepatitis. Histopathology, 2011, 58(5):693-704.

Application of steroids in treatment of patients with liver failure

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 20

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Ji Yuxin, Li Shuchen. Efficacy of glucocorticoid in dealing with patients with liver failure [J]. Journal of Practical Hepatology, 2020, 23(1): 10-13.
[2]	Li Yonghua, Sun Yanfen, Wang Jiajia, et al. Efficacy of entecavir and matrine combination therapy in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2020, 23(1): 22-25.
[3]	Wei Zhongcao, Liu Na, Xing Xin, et al. Efficacy and safety ofpolyene phosphatidylcholine combined with metformin in the treatment of patients with non-alcoholic fatty liver disease: a Meta-analysis [J]. Journal of Practical Hepatology, 2020, 23(1): 46-49.
[4]	Sun Hongju, Wang Yanyan, Xu Congcong, et al. Efficacy of tiopronin and metoprolol combination in treatment of patients with alcoholic liver disease [J]. Journal of Practical Hepatology, 2020, 23(1): 54-57.
[5]	Wang Jianhui, Guo Hongdan, Kong Jingjing, et al. Clinical characteristics and risk factors ofdrug-induced liver injury caused by antituberculosis therapy [J]. Journal of Practical Hepatology, 2020, 23(1): 58-61.
[6]	Ma Yuanji, Xu Yan, Bai Lang, et al. Comparison of citrate to heparin as a catheter locking solution in patients with liver failure undergoing artificial liver support therapy [J]. Journal of Practical Hepatology, 2020, 23(1): 66-69.
[7]	Ma Ning, Dai Xiaowen , Wu Jianjiang. Influence of different types of liquid infusion on clinical efficacy and safety of patients withhepatocellular carcinoma undergoing partial hepatectomy [J]. Journal of Practical Hepatology, 2020, 23(1): 102-105.
[8]	Bao Yingjun, Ren Weixin.. Interventional therapy for patients with portal vein thrombosis [J]. Journal of Practical Hepatology, 2019, 22(6): 768-769.
[9]	National Workshop on Fatty Liver, Alcoholic Liver Disease, Chinese Society of Hepatology; National Workshop on Liver, Metabolism, Chinese Society of Endocrinology, Chinese Medical Association. Committee of Hepatology, Chinese Research Hospital Association; Fatty Liver Expert Committee, Chinese Medical Doctor Association [J]. Journal of Practical Hepatology, 2019, 22(6): 787-792.
[10]	Shi Yingying, Wang Yuanxi.. Impact of combination telbivudine and adefovir dipivoxil on renal functions in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 820-823.
[11]	Xing Xin, Wei Zhongcao, Zhou mimi, et al.. Efficacy and safety of tauroursodeoxycholic acid and ursodeoxycholic acid combination in the treatment of patients with nonalcoholic fatty liver disease:a Meta-analysis [J]. Journal of Practical Hepatology, 2019, 22(6): 852-855.
[12]	Duan Chuyao, Chen Qingshan, Wang Liming, et al.. Clinical efficacy of ursodeoxycholic acid in treatment of patients with intrahepatic cholestasis of pregnancy [J]. Journal of Practical Hepatology, 2019, 22(6): 864-867.
[13]	Chen Meimei, Duan Xiaoyan, Cao Haixia, et al.. Improvement of clinical symptoms and serum hepatic fibrosis markers in patients with primary biliary cirrhosis by compound Biejiaruangan tablets [J]. Journal of Practical Hepatology, 2019, 22(6): 880-883.
[14]	Ma Yaqiong, Li Zhilan, Xia Bing.. Early administration of enteral nutrition and microecological agents in patients with hepatic encephalopathy [J]. Journal of Practical Hepatology, 2019, 22(6): 892-895.
[15]	Feng Wenguang, Jiang Wei, Song Guojun.. PPV-guided fluid therapy in patients with hepatolithiasis underwent partial hepatectomy [J]. Journal of Practical Hepatology, 2019, 22(6): 912-915.